BACKGROUND: In the current study, the authors examined the outcomes of patients with desmoid tumors who received systemic therapy at a single institution to provide a basis for the examination of newer agents. METHODS: Records of patients with desmoid tumors who were treated with chemotherapy at the study institution were reviewed. The activity of nonsteroidal anti-inflammatory drugs was not addressed. Patients without measurable disease and those receiving therapy could not be documented, and those receiving prophylactic therapy were excluded. RESULTS: A total of 68 patients received 157 lines of therapy. At the time of last follow-up, 9 patients had died, 7 of progressive disease. The cohort was 62% female, with a median age of 32.5 years. Approximately 32% of the patients had Gardner syndrome. The median follow-up was 63 months, and patients received a median of 2 lines of therapy. An intra-abdominal primary tumor location was the most common (44%). The greatest Response Evaluation Criteria in Solid Tumors (RECIST) response rate was observed with anthracyclines and hormonal therapy and the lowest response was noted with single-agent dacarbazine/temozolomide or tyrosine kinase inhibitors, principally imatinib. On multivariate analysis, macroscopic nodular morphology and the presence of Gardner syndrome were the only tumor factors found to be associated with a greater time to disease progression. CONCLUSIONS: Compared with other agents, antiestrogens and anthracycline-containing regimens appear to be associated with a higher radiological response rate against desmoid tumors. Systemic therapy can be successful in patients with desmoid tumors, and is a viable option in lieu of morbid or disabling surgery. (c) 2010 American Cancer Society.
BACKGROUND: In the current study, the authors examined the outcomes of patients with desmoid tumors who received systemic therapy at a single institution to provide a basis for the examination of newer agents. METHODS: Records of patients with desmoid tumors who were treated with chemotherapy at the study institution were reviewed. The activity of nonsteroidal anti-inflammatory drugs was not addressed. Patients without measurable disease and those receiving therapy could not be documented, and those receiving prophylactic therapy were excluded. RESULTS: A total of 68 patients received 157 lines of therapy. At the time of last follow-up, 9 patients had died, 7 of progressive disease. The cohort was 62% female, with a median age of 32.5 years. Approximately 32% of the patients had Gardner syndrome. The median follow-up was 63 months, and patients received a median of 2 lines of therapy. An intra-abdominal primary tumor location was the most common (44%). The greatest Response Evaluation Criteria in Solid Tumors (RECIST) response rate was observed with anthracyclines and hormonal therapy and the lowest response was noted with single-agent dacarbazine/temozolomide or tyrosine kinase inhibitors, principally imatinib. On multivariate analysis, macroscopic nodular morphology and the presence of Gardner syndrome were the only tumor factors found to be associated with a greater time to disease progression. CONCLUSIONS: Compared with other agents, antiestrogens and anthracycline-containing regimens appear to be associated with a higher radiological response rate against desmoid tumors. Systemic therapy can be successful in patients with desmoid tumors, and is a viable option in lieu of morbid or disabling surgery. (c) 2010 American Cancer Society.
Authors: S Tejpar; F Nollet; C Li; J S Wunder; G Michils; P dal Cin; E Van Cutsem; B Bapat; F van Roy; J J Cassiman; B A Alman Journal: Oncogene Date: 1999-11-11 Impact factor: 9.867
Authors: L Bertario; A Russo; P Sala; L Varesco; M Giarola; P Mondini; M Pierotti; P Spinelli; P Radice Journal: J Clin Oncol Date: 2003-05-01 Impact factor: 44.544
Authors: Alexander J F Lazar; Daniel Tuvin; Shohrae Hajibashi; Sultan Habeeb; Svetlana Bolshakov; Empar Mayordomo-Aranda; Carla L Warneke; Dolores Lopez-Terrada; Raphael E Pollock; Dina Lev Journal: Am J Pathol Date: 2008-10-02 Impact factor: 4.307
Authors: R Caspari; S Olschwang; W Friedl; M Mandl; C Boisson; T Böker; A Augustin; M Kadmon; G Möslein; G Thomas Journal: Hum Mol Genet Date: 1995-03 Impact factor: 6.150
Authors: Justin M M Cates; Jennifer O Black; Doha M Itani; John H Fasig; Vicki L Keedy; Kenneth R Hande; Brent W Whited; Kelly C Homlar; Jennifer L Halpern; Ginger E Holt; Herbert S Schwartz; Cheryl M Coffin Journal: Hum Pathol Date: 2012-04-18 Impact factor: 3.466
Authors: Mrinal M Gounder; Michelle R Mahoney; Brian A Van Tine; Vinod Ravi; Steven Attia; Hari A Deshpande; Abha A Gupta; Mohammed M Milhem; Robert M Conry; Sujana Movva; Michael J Pishvaian; Richard F Riedel; Tarek Sabagh; William D Tap; Natally Horvat; Ethan Basch; Lawrence H Schwartz; Robert G Maki; Narasimhan P Agaram; Robert A Lefkowitz; Yousef Mazaheri; Rikiya Yamashita; John J Wright; Amylou C Dueck; Gary K Schwartz Journal: N Engl J Med Date: 2018-12-20 Impact factor: 91.245
Authors: Nicholas A Mignemi; Doha M Itani; John H Fasig; Vicki L Keedy; Kenneth R Hande; Brent W Whited; Kelly C Homlar; Hernan Correa; Cheryl M Coffin; Jennifer O Black; Yajun Yi; Jennifer L Halpern; Ginger E Holt; Herbert S Schwartz; Jonathan G Schoenecker; Justin M M Cates Journal: Cancer Sci Date: 2012-11-15 Impact factor: 6.716
Authors: Aimeé M Crago; Brian Denton; Sébastien Salas; Armelle Dufresne; James J Mezhir; Meera Hameed; Mithat Gonen; Samuel Singer; Murray F Brennan Journal: Ann Surg Date: 2013-08 Impact factor: 12.969